SCHEMBL2301080

SCHEMBL2301080

CC(C)(C)OC(=O)NC12CNCC1C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
GAA P10253 2/20 0.36
EPHX2 P34913 2/20 0.33
NFKB1 P19838 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
BTK Q06187 1/20 0.31
CACNA1H O95180 1/20 0.31
IDO1 P14902 1/20 0.30
HDAC4 P56524 1/20 0.30
HDAC1 Q13547 1/20 0.30
PSEN1 P49768 1/20 0.30
PSEN2 P49810 1/20 0.30
APH1B Q8WW43 1/20 0.30
NCSTN Q92542 1/20 0.30
APH1A Q96BI3 1/20 0.30
PSENEN Q9NZ42 1/20 0.30
DPP8 Q6V1X1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30325623 1.00 MEN1 (0.39) MEN1MAPK1KMT2AGAAEPHX2
SCHEMBL25201032 1.00 MEN1 (0.39) MEN1MAPK1KMT2AGAAEPHX2
SCHEMBL21335536 1.00 MEN1 (0.39) MEN1MAPK1KMT2AGAAEPHX2
SCHEMBL26607392 1.00 MEN1 (0.39) MEN1MAPK1KMT2AGAAEPHX2
SCHEMBL2670204 0.86 MEN1 (0.35) MEN1MAPK1KMT2AGAABTK
SCHEMBL4748874 0.86 MEN1 (0.37) MEN1MAPK1KMT2AGAAEPHX2
SCHEMBL2670376 0.86 MEN1 (0.37) MEN1MAPK1KMT2AGAAEPHX2
SCHEMBL4918795 0.85 MEN1 (0.38) MEN1MAPK1KMT2AGAAEPHX2
SCHEMBL2670103 0.85 MEN1 (0.38) MEN1MAPK1KMT2AGAAEPHX2
SCHEMBL7517321 0.85 PSEN1 (0.35) MEN1MAPK1KMT2AGAAEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720058-A2 BIFUNCTIONAL DEGRADERS AND USES THEREOF Casma Therapeutics, Inc. (US) 2026-04-08 EP disclosed
US-12312336-B2 Inhibitors of RAF kinases Pierre Fabre Médicament (FR) 2025-05-27 US disclosed
US-12281116-B2 HTT modulators for treating Huntington's disease CHDI FOUNDATION, INC. (US) 2025-04-22 US disclosed
US-20250084041-A1 ANTIMICROBIAL COMPOUNDS AND METHODS THE UNIVERSITY OF UTAH RESEARCH FOUNDATION 2025-03-13 US disclosed
WO-2024249291-A2 BIFUNCTIONAL DEGRADERS AND USES THEREOF CASMA THERAPEUTICS, INC. (US) 2024-12-05 WO disclosed
EP-4457217-A1 ANTIMICROBIAL COMPOUNDS AND METHODS Curza Global LLC (US) 2024-11-06 EP disclosed
EP-4433471-A1 N-(2H-INDAZOL-5-YL)PYRAZINE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS HTT MODULATORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE CHDI Foundation, Inc. (US) 2024-09-25 EP disclosed
WO-2024175450-A1 SUBSTITUTED S-ALANINATE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2024-08-29 WO disclosed
US-12037345-B2 Heterobicyclic compounds for inhibiting the activity of SHP2 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-16 US disclosed
US-20240228463-A1 SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME GENENTECH, INC. (US) 2024-07-11 US disclosed
EP-1304329-B1 Pyridonecarboxylic acid derivatives and their use as antibacterial agents DAIICHI SANKYO CO LTD (JP) 2008-10-15 EP disclosed
EP-1831216-A2 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2007-09-12 EP disclosed
WO-2006067614-A2 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2006-06-29 WO disclosed
EP-0924213-B1 PYRIDOBENZOXAZINE DERIVATIVES DAIICHI SEIYAKU CO (JP) 2006-06-28 EP disclosed
EP-0807630-B1 HETEROCYCLIC COMPOUNDS DAIICHI SEIYAKU CO (JP) 2003-05-07 EP disclosed
EP-1304329-A2 Pyridonecarboxylic acid derivatives and their use as antibacterial agents DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-23 EP disclosed
US-6191129-B1 MICROBIOCIDES, BACTERICIDES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-02-20 US disclosed
EP-0924213-A1 PYRIDOBENZOXAZINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1999-06-23 EP disclosed
US-5849757-A Pyridonecarboxylic acid derivatives substituted by a bicyclic amino group as antibacterials DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1998-12-15 US disclosed
EP-0807630-A1 HETEROCYCLIC COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1997-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12281116-B2 HTT modulators for treating Huntington's disease HTT, HYPK, ATXN2 MEN1 4321/4885MAPK1 3546/4885KMT2A 1178/4885
US-20240228463-A1 SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME CACNA1I, CACNA1B, CACNA1C MEN1 1307/4885MAPK1 2075/4885KMT2A 2619/4885
US-12312336-B2 Inhibitors of RAF kinases BRAF, RAF1, ARAF MEN1 2171/4885MAPK1 268/4885KMT2A 1631/4885
US-20250084041-A1 ANTIMICROBIAL COMPOUNDS AND METHODS MPO, NISCH, RPN2 MEN1 4216/4885MAPK1 2873/4885KMT2A 4067/4885
US-12037345-B2 Heterobicyclic compounds for inhibiting the activity of SHP2 PTPN1, PTPN9, PTPN7 MEN1 2874/4885MAPK1 321/4885KMT2A 1327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.